Disease & Solutions Products Professional Education Innovation Ecosystem Investor Relations News Careers About Us
You are about to leave Peijia Medical's official Chinese website.
You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.
Cancel
Continue
Brief News on Innovation
Company News Brief News on Innovation
TaurusTrio™ TAVR SYSTEM (TaurusTrio™) SUCCESSFULLYCOMPLETED THE FIRST FEE-BASED COMPASSIONATE USETREATMENT IN HONG KONG
2024-11-28 16:22:47

In November 2024, Peijia Medical successfully implanted the TaurusTrio™, a self-developedtranscatheter aortic valve system specifically designed for the treatment of aortic regurgitation(AR), in Hong Kong. The implantation was performed by Professor Yat-Yin Lam, the Director ofthe Department of Cardiology at the Canossa Hospital in Hong Kong, in conjunction with ananesthesiology and ultrasound multidisciplinary team at Hong Kong Adventist Hospital, markingthe first fee-based compassionate use treatment of the TaurusTrio™ in Hong Kong.

The procedure invited Professor Song Guangyuan, the Director of the Interventional HeartValve Disease Center at Beijing Anzhen Hospital, for technical exchange and guidance. Theycompleted this procedure together. The overall procedure went smoothly, with the artificialvalve being ideally and well-positioned after implantation. AR disappeared immediately afterthe procedure.

The procedure demonstrated the safety anduser-friendliness of the TaurusTrio™,significantly shortening the learning curve forphysicians, and also making the futureapplication and popularization of TAVR morerapid.

企业微信截图_20250102162753.png


Prev：PCR London Valves : HighLife® TSMVR SYSTEM (HighLife®) ANNOUNCED THE 1- YEAR CLINICAL FOLLOW-UP RESULTS OF THE FIRST 45 PATIENTS FROM A FEASIBILITY STUDY FOR THE FIRST TIME, LAYING A SOLID EVIDENCE-BASED FOUNDATION FOR FUTURE CE APPROVAL
Next：PROFESSOR GE JUNBO'S TEAM SUCCESSFULLY COMPLETED THE FIRST NATIONAL IMPLANTATION OF THE TAURUSMAXTM TRANSCATHETER AORTIC VALVE REPLACEMENT SYSTEM
Top